Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
Identifieur interne : 001036 ( PubMed/Corpus ); précédent : 001035; suivant : 001037Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
Auteurs : Christophe Jollivet ; Anne Aubert-Pouessel ; Anne Clavreul ; Marie-Claire Venier-Julienne ; Claudia N. Montero-Menei ; Jean-Pierre Benoit ; Philippe MeneiSource :
- Neuroscience letters [ 0304-3940 ] ; 2004.
English descriptors
- KwdEn :
- Amphetamine, Analysis of Variance, Animals, Behavior, Animal, Cell Count (methods), Corpus Striatum (anatomy & histology), Corpus Striatum (drug effects), Disease Models, Animal, Female, Glial Cell Line-Derived Neurotrophic Factor, Immunohistochemistry (methods), Microspheres, Nerve Growth Factors (therapeutic use), Nerve Regeneration (drug effects), Oxidopamine, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Rats, Rats, Sprague-Dawley, Stereotaxic Techniques, Stereotyped Behavior (drug effects), Time, Time Factors, Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : Nerve Growth Factors.
- chemical : Amphetamine, Glial Cell Line-Derived Neurotrophic Factor, Oxidopamine.
- anatomy & histology : Corpus Striatum.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Corpus Striatum, Nerve Regeneration, Stereotyped Behavior.
- drug therapy : Parkinson Disease, Secondary.
- methods : Cell Count, Immunohistochemistry.
- Analysis of Variance, Animals, Behavior, Animal, Disease Models, Animal, Female, Microspheres, Rats, Rats, Sprague-Dawley, Stereotaxic Techniques, Time, Time Factors.
Abstract
Glial cell line-derived neurotrophic factor (GDNF) offers the possibility to stimulate axonal regeneration of mesencephalic dopaminergic neurons, which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. In a previous study, we showed that GDNF-releasing microspheres can deliver the neurotrophic factor for 2 months, allowing in a partial rat model of Parkinson's disease a sprouting of the preserved dopaminergic fibers and functional improvement 8 weeks after the treatment. The present study confirms these previous observations and shows that the amphetamine-induced rotation score is still decreased 24 weeks after the end of GDNF delivery. Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used.
DOI: 10.1016/j.neulet.2003.11.051
PubMed: 15036631
Links to Exploration step
pubmed:15036631Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.</title><author><name sortKey="Jollivet, Christophe" sort="Jollivet, Christophe" uniqKey="Jollivet C" first="Christophe" last="Jollivet">Christophe Jollivet</name><affiliation><nlm:affiliation>INSERM ERIT-M 0104, Bâtiment IBT, 10 rue Andre Boquel, 49100 Angers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Aubert Pouessel, Anne" sort="Aubert Pouessel, Anne" uniqKey="Aubert Pouessel A" first="Anne" last="Aubert-Pouessel">Anne Aubert-Pouessel</name></author><author><name sortKey="Clavreul, Anne" sort="Clavreul, Anne" uniqKey="Clavreul A" first="Anne" last="Clavreul">Anne Clavreul</name></author><author><name sortKey="Venier Julienne, Marie Claire" sort="Venier Julienne, Marie Claire" uniqKey="Venier Julienne M" first="Marie-Claire" last="Venier-Julienne">Marie-Claire Venier-Julienne</name></author><author><name sortKey="Montero Menei, Claudia N" sort="Montero Menei, Claudia N" uniqKey="Montero Menei C" first="Claudia N" last="Montero-Menei">Claudia N. Montero-Menei</name></author><author><name sortKey="Benoit, Jean Pierre" sort="Benoit, Jean Pierre" uniqKey="Benoit J" first="Jean-Pierre" last="Benoit">Jean-Pierre Benoit</name></author><author><name sortKey="Menei, Philippe" sort="Menei, Philippe" uniqKey="Menei P" first="Philippe" last="Menei">Philippe Menei</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15036631</idno><idno type="pmid">15036631</idno><idno type="doi">10.1016/j.neulet.2003.11.051</idno><idno type="wicri:Area/PubMed/Corpus">001036</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001036</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.</title><author><name sortKey="Jollivet, Christophe" sort="Jollivet, Christophe" uniqKey="Jollivet C" first="Christophe" last="Jollivet">Christophe Jollivet</name><affiliation><nlm:affiliation>INSERM ERIT-M 0104, Bâtiment IBT, 10 rue Andre Boquel, 49100 Angers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Aubert Pouessel, Anne" sort="Aubert Pouessel, Anne" uniqKey="Aubert Pouessel A" first="Anne" last="Aubert-Pouessel">Anne Aubert-Pouessel</name></author><author><name sortKey="Clavreul, Anne" sort="Clavreul, Anne" uniqKey="Clavreul A" first="Anne" last="Clavreul">Anne Clavreul</name></author><author><name sortKey="Venier Julienne, Marie Claire" sort="Venier Julienne, Marie Claire" uniqKey="Venier Julienne M" first="Marie-Claire" last="Venier-Julienne">Marie-Claire Venier-Julienne</name></author><author><name sortKey="Montero Menei, Claudia N" sort="Montero Menei, Claudia N" uniqKey="Montero Menei C" first="Claudia N" last="Montero-Menei">Claudia N. Montero-Menei</name></author><author><name sortKey="Benoit, Jean Pierre" sort="Benoit, Jean Pierre" uniqKey="Benoit J" first="Jean-Pierre" last="Benoit">Jean-Pierre Benoit</name></author><author><name sortKey="Menei, Philippe" sort="Menei, Philippe" uniqKey="Menei P" first="Philippe" last="Menei">Philippe Menei</name></author></analytic><series><title level="j">Neuroscience letters</title><idno type="ISSN">0304-3940</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphetamine</term><term>Analysis of Variance</term><term>Animals</term><term>Behavior, Animal</term><term>Cell Count (methods)</term><term>Corpus Striatum (anatomy & histology)</term><term>Corpus Striatum (drug effects)</term><term>Disease Models, Animal</term><term>Female</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Immunohistochemistry (methods)</term><term>Microspheres</term><term>Nerve Growth Factors (therapeutic use)</term><term>Nerve Regeneration (drug effects)</term><term>Oxidopamine</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Stereotaxic Techniques</term><term>Stereotyped Behavior (drug effects)</term><term>Time</term><term>Time Factors</term><term>Tyrosine 3-Monooxygenase (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nerve Growth Factors</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Amphetamine</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Oxidopamine</term></keywords><keywords scheme="MESH" qualifier="anatomy & histology" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Nerve Regeneration</term><term>Stereotyped Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell Count</term><term>Immunohistochemistry</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Behavior, Animal</term><term>Disease Models, Animal</term><term>Female</term><term>Microspheres</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Stereotaxic Techniques</term><term>Time</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glial cell line-derived neurotrophic factor (GDNF) offers the possibility to stimulate axonal regeneration of mesencephalic dopaminergic neurons, which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. In a previous study, we showed that GDNF-releasing microspheres can deliver the neurotrophic factor for 2 months, allowing in a partial rat model of Parkinson's disease a sprouting of the preserved dopaminergic fibers and functional improvement 8 weeks after the treatment. The present study confirms these previous observations and shows that the amphetamine-induced rotation score is still decreased 24 weeks after the end of GDNF delivery. Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15036631</PMID><DateCreated><Year>2004</Year><Month>03</Month><Day>23</Day></DateCreated><DateCompleted><Year>2004</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>356</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci. Lett.</ISOAbbreviation></Journal><ArticleTitle>Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>207-10</MedlinePgn></Pagination><Abstract><AbstractText>Glial cell line-derived neurotrophic factor (GDNF) offers the possibility to stimulate axonal regeneration of mesencephalic dopaminergic neurons, which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. In a previous study, we showed that GDNF-releasing microspheres can deliver the neurotrophic factor for 2 months, allowing in a partial rat model of Parkinson's disease a sprouting of the preserved dopaminergic fibers and functional improvement 8 weeks after the treatment. The present study confirms these previous observations and shows that the amphetamine-induced rotation score is still decreased 24 weeks after the end of GDNF delivery. Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jollivet</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM ERIT-M 0104, Bâtiment IBT, 10 rue Andre Boquel, 49100 Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubert-Pouessel</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Clavreul</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Venier-Julienne</LastName><ForeName>Marie-Claire</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Montero-Menei</LastName><ForeName>Claudia N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Menei</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495041">Gdnf protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy & histology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008863" MajorTopicYN="Y">Microspheres</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013238" MajorTopicYN="N">Stereotaxic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013239" MajorTopicYN="N">Stereotyped Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="Y">Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15036631</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2003.11.051</ArticleId><ArticleId IdType="pii">S0304394003013776</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001036 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001036 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15036631
|texte= Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15036631" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |